Adam Sinding Steensberg
Chief Executive Officer presso ZEALAND PHARMA A/S
Patrimonio netto: 4 M $ in data 31/03/2024
Provenienza dei contatti di primo grado di Adam Sinding Steensberg
| Entità | Tipo di entità | Settore Industriale | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Major | 51 | |
International Institute for Management Development
14
| College/University | Other Consumer Services | 14 |
| Public Company | Pharmaceuticals: Major | 12 | |
Dansk Biotek
 Dansk Biotek Miscellaneous Commercial ServicesCommercial Services Dansk Biotek is an industry association for biotech companies with promoting the biotechnological research, development and production in taking care of corporate interests in this regard, both nationally and internationally. The company was founded in 1987 and is headquartered in Copenhagen, Denmark.
10
| Private Company | Miscellaneous Commercial Services | 10 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Adam Sinding Steensberg tramite i suoi contatti personali
| Società | Settore | Persone collegate | Posizione principale |
|---|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| ASTRAZENECA PLC | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| NOVO NORDISK A/S | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Public Communications Contact Corporate Officer/Principal Director of Finance/CFO Corporate Officer/Principal Corporate Officer/Principal | |
| H. LUNDBECK A/S | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Corporate Officer/Principal Corporate Officer/Principal Public Communications Contact Director/Board Member Corporate Officer/Principal | |
| SANOFI | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
| SHIRE | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| GENMAB A/S | Pharmaceuticals: Major | Chairman Investor Relations Contact | |
| NTG NORDIC TRANSPORT GROUP A/S | Trucking | Investor Relations Contact Chief Tech/Sci/R&D Officer | |
| BIOINVENT INTERNATIONAL AB | Biotechnology | Chairman Director/Board Member | |
| SILENCE THERAPEUTICS PLC | Miscellaneous Commercial Services | Chief Executive Officer Chief Operating Officer | |
| BIOPORTO A/S | Medical Specialties | Director/Board Member Director/Board Member Director/Board Member | |
| ALK-ABELLÓ A/S | Biotechnology | Director of Finance/CFO Corporate Officer/Principal | |
| ATON | Pharmaceuticals: Major | Director/Board Member Chairman | |
| BASILEA PHARMACEUTICA AG | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| Copenhagen Business School | College/University | Graduate Degree Graduate Degree Graduate Degree Graduate Degree Masters Business Admin Graduate Degree Graduate Degree Masters Business Admin | |
| University of Uppsala | College/University | Doctorate Degree Doctorate Degree | |
| University of Aarhus | College/University | Corporate Officer/Principal Masters Business Admin Undergraduate Degree Graduate Degree | |
| AVEO PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Comptroller/Controller/Auditor Human Resources Officer | |
| Technical University of Denmark | College/University | Graduate Degree Graduate Degree Graduate Degree Graduate Degree | |
| CELLECTIS S.A. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| University of Copenhagen | College/University | Doctorate Degree Doctorate Degree Doctorate Degree Undergraduate Degree Corporate Officer/Principal Doctorate Degree Doctorate Degree Graduate Degree Corporate Officer/Principal Doctorate Degree Doctorate Degree Doctorate Degree Doctorate Degree Doctorate Degree Graduate Degree Doctorate Degree Graduate Degree Graduate Degree | |
Takeda A/S
 Takeda A/S Financial ConglomeratesFinance Takeda A/S engages in holding or owning of securities in other companies other than banks. The company was founded on January 4, 2005 and is headquartered in Taastrup, Denmark. | Financial Conglomerates | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| University of Southern Denmark | College/University | Masters Business Admin Undergraduate Degree Doctorate Degree Graduate Degree | |
| Danmarks Farmaceutiske Universitet | College/University | Undergraduate Degree Graduate Degree Undergraduate Degree | |
Symphogen A/S
 Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | Pharmaceuticals: Major | Chief Executive Officer Chief Executive Officer | |
| University of Lisbon | College/University | Graduate Degree Corporate Officer/Principal | |
OxThera AB
 OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Pharmaceuticals: Generic | Director/Board Member Director/Board Member | |
EpiTherapeutics ApS
 EpiTherapeutics ApS BiotechnologyHealth Technology EpiTherapeutics ApS is a holding company that develops cancer drugs based on research in the field of epigenetics. Its development programs are focused on enzymes involved in the regulation of transcription in cancer - current programs target histone demethylases and methyltransferases. The firm's regulation is commonly used for post-translational covalent modifications of histones and other chromatin-remodeling complexes, which determines whether a gene is accessible and hence, expressed or repressed. Its covalent modifications involved in epigenetic regulation include deoxyribonucleic acid methylation, histone acetylation, and histone methylation. The company was founded by Kristian Helin, Paul Andreas Compare Cloos, Jesper Aagaard Christensen, Karl Agger, and Klaus Hansen on September 18, 2008 and is headquartered in Greve, Denmark. | Biotechnology | Corporate Officer/Principal Director/Board Member | |
| ORPHAZYME A/S | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
| EGETIS THERAPEUTICS AB | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Kymab Ltd.
 Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Major | Chief Executive Officer Chairman Director/Board Member Founder | |
| Copenhagen University Hospital | College/University | Corporate Officer/Principal Doctorate Degree | |
| AVT Business School A/S | College/University | Chairman Masters Business Admin Masters Business Admin | |
OncoNOx ApS
 OncoNOx ApS Pharmaceuticals: MajorHealth Technology OncoNOx ApS provides drugs for the treatment of autoimmune diseases and cancer. It is a pharmaceutical company that transforms marketed drugs into proprietary molecules with anti-cancer and/or anti-inflammatory properties. The firm's projects include OX1001 and OX27-NO is a potent anti-cancer compounds in vitro and in vivo and are intended for the treatment of cancer, and OX1001 also exhibits anti-viral activity and is in development for treatment of human immunodeficiency virus (HIV) and acquired immune deficiency syndrome patients with or without HIV related cancer. The company was founded by Ferdinando Nicoletti, Gianni Garotta, Yousef Al-Abed, Marco Donia, and Mai-Britt Zocca in 2011 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Founder Founder | |
| VALNEVA | Biotechnology | Corporate Officer/Principal Director/Board Member | |
| Harvard Business School | College/University | Masters Business Admin Masters Business Admin | |
| Richard Ivey School of Business | College/University | Masters Business Admin Corporate Officer/Principal | |
IO Biotech ApS
 IO Biotech ApS BiotechnologyHealth Technology IO Biotech ApS operates as a clinical stage biotech company. It develops immunotherapy for cancer by targeting a mechanism used by tumour cells to evade immune responses. The company was founded by Mai-Britt Zocca, Mads Hald Andersen, Inge Marie Svane, Anders Ljungqvist and Per Thor Straten and is headquartered in Copenhagen, Denmark. | Biotechnology | Chief Executive Officer Chairman | |
Step Pharma SAS
 Step Pharma SAS Pharmaceuticals: MajorHealth Technology Step Pharma SAS develops drugs for immunosuppressive therapies. The company was founded by Geoffroy de Ribains, Alain Fischer, and Sylvain Latour and is headquartered in Paris, France. | Pharmaceuticals: Major | Chief Executive Officer Chairman | |
NorthSea Therapeutics BV
 NorthSea Therapeutics BV BiotechnologyHealth Technology NorthSea Therapeutics BV operates as a biotechnology company. It develops oral, structurally engineered fatty acid therapeutics. The company was founded by Hilde H. Steineger and David A. Fraser and is headquartered in Naarden, the Netherlands. | Biotechnology | Director of Finance/CFO Director/Board Member | |
| ALTAMIRA THERAPEUTICS LTD. | Biotechnology | Director/Board Member Director/Board Member | |
Kymab Group Ltd.
 Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The private company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Auris Medical AG
 Auris Medical AG Medical SpecialtiesHealth Technology Auris Medical AG manufactures electronic devices for ear disorders. It develops novel pharmaceutical therapies to protect hearing and to silence tinnitus. The company was founded by Thomas Meyer in April 2003 and is headquartered in Basel, Switzerland. | Medical Specialties | Director/Board Member Director/Board Member |
Statistiche
Distribuzione geografica
| Danimarca | 22 |
| Svezia | 7 |
| Francia | 6 |
| Regno Unito | 5 |
| Stati Uniti | 4 |
Settori
| Health Technology | 36 |
| Consumer Services | 13 |
| Transportation | 2 |
| Commercial Services | 2 |
| Finance | 2 |
Posizioni
| Director/Board Member | 341 |
| Corporate Officer/Principal | 173 |
| Independent Dir/Board Member | 106 |
| Chief Executive Officer | 81 |
| Chairman | 73 |
Contatti più connessi
| Insiders | |
|---|---|
| Alain Munoz | 38 |
| Alf Gunnar Martin Nicklasson | 31 |
| Catherine Moukheibir | 29 |
| Jeffrey Berkowitz | 26 |
| Martin Olin | 25 |
| Rosemary Crane | 23 |
| Leonard Kruimer | 22 |
| Jørgen Lindegaard | 22 |
| David Solomon | 22 |
| Jutta af Rosenborg | 21 |
| Søren Møller | 21 |
| Michael Owen | 20 |
| Peter Nordkild | 20 |
| Matti Juhani Alahuhta | 18 |
| Kirsten Drejer | 18 |
- Borsa valori
- Insiders
- Adam Sinding Steensberg
- Connessioni Società
